Venus Remedies Ltd's Q3FY25 Quarter Results
- 05 Feb 2025
Result Summary
- Venus Remedies Ltd reported a 0.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 22.7%.
- Its expenses for the quarter were down by 3.0% QoQ and up 18.8% YoY.
- The net profit increased 456.8% QoQ and increased 186.1% YoY.
- The earnings per share (EPS) of Venus Remedies Ltd stood at 14.7 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 178.89 | 178.03 | 145.77 | 0.5% | 22.7% |
Total Expenses | 163.92 | 168.96 | 137.99 | -3.0% | 18.8% |
Profit Before Tax | 24.88 | 9.08 | 7.78 | 174.0% | 219.8% |
Tax | 5.28 | 5.56 | 0.93 | -5.0% | 467.7% |
Profit After Tax | 19.60 | 3.52 | 6.85 | 456.8% | 186.1% |
Earnings Per Share | 14.70 | 2.60 | 5.10 | 465.4% | 188.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Venus Remedies Ltd is a pharmaceutical company involved in the production and distribution of a diverse range of pharmaceutical formulations. The company operates within the healthcare industry, focusing on providing innovative and effective solutions to address various medical needs. It specializes in research and development, manufacturing, and marketing of pharmaceutical products, including antibiotics, oncology drugs, and critical care medications. Venus Remedies Ltd is known for its strong presence in domestic and international markets, with a commitment to delivering quality healthcare products. Recent major developments within the company include expanding its market reach and strengthening its research capabilities, although specific details from recent months are not available.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Venus Remedies Ltd reported a total income of ₹178.89 crores. This reflects a quarter-over-quarter (QoQ) increase of 0.5% compared to ₹178.03 crores in Q2FY25. On a year-over-year (YoY) basis, the total income increased by 22.7% from ₹145.77 crores in Q3FY24. The steady growth in revenue highlights the company's ability to generate higher sales and improve its market position over the past year. The upward trend in revenue indicates a consistent demand for its products and services in the pharmaceutical sector.
Profitability
During Q3FY25, Venus Remedies Ltd achieved a profit before tax of ₹24.88 crores, marking a significant QoQ growth of 174.0% from ₹9.08 crores in Q2FY25. On a YoY basis, the profit before tax increased by 219.8% compared to ₹7.78 crores in Q3FY24. The tax expense for Q3FY25 was ₹5.28 crores, showing a slight QoQ decrease of 5.0% from ₹5.56 crores in the previous quarter, but a significant YoY increase of 467.7% from ₹0.93 crores in Q3FY24. Consequently, the profit after tax surged to ₹19.60 crores in Q3FY25, representing a remarkable QoQ growth of 456.8% and a YoY increase of 186.1%. The earnings per share for the quarter stood at ₹14.70, reflecting a substantial QoQ growth of 465.4% and a YoY increase of 188.2% from the previous year.
Operating Metrics
Venus Remedies Ltd reported total expenses of ₹163.92 crores in Q3FY25, a decrease of 3.0% QoQ from ₹168.96 crores in Q2FY25. However, on a YoY basis, total expenses increased by 18.8% from ₹137.99 crores in Q3FY24. The reduction in expenses on a QoQ basis suggests effective cost management strategies by the company during the quarter. The overall increase in expenses YoY could be attributed to various operational factors, including inflationary pressures, increased production costs, or expanded business operations. These operating metrics provide insight into the company's efficiency in managing its resources and expenditures while driving profitability growth.
